Baton Rouge-based OncBioMune Pharmaceuticals Inc. has been granted a patent for its novel chemotherapy delivery system.
The patent covers the clinical stage biopharma firm’s unique chemotherapy composition. OncBioMune said its transport technology does a better job of targeting tumor cells than commonly used therapies, which also can kill healthy cells and cause a range of complications including death.
OncBioMune is preparing to enter two separate Phase 2 trials of its lead prostate cancer vaccine, ProscaVax, and also working on the chemotherapy delivery technology, said Dr. Jonathan Head, the company’s chief executive officer.
Phase 2 trials show whether the vaccine is effective.